Unique ID issued by UMIN | UMIN000008049 |
---|---|
Receipt number | R000009480 |
Scientific Title | Efficacy of Ezetimibe vs Rosuvastatin In Impaired Glucose Tolerance Hypercholesterolemia to Treat |
Date of disclosure of the study information | 2012/05/30 |
Last modified on | 2016/08/25 10:54:30 |
Efficacy of Ezetimibe vs Rosuvastatin In Impaired Glucose Tolerance Hypercholesterolemia to Treat
Efficacy of Ezetimibe vs Rosuvastatin In Impaired Glucose Tolerance Hypercholesterolemia to Treat (E-RIGHT study)
Efficacy of Ezetimibe vs Rosuvastatin In Impaired Glucose Tolerance Hypercholesterolemia to Treat
Efficacy of Ezetimibe vs Rosuvastatin In Impaired Glucose Tolerance Hypercholesterolemia to Treat (E-RIGHT study)
Japan |
Hypercholesterolemia
Medicine in general | Cardiology | Endocrinology and Metabolism |
Others
NO
1. To investigate the clinical effect of ezetimibe on LDL-cholesterol(LDL-C), other serum lipids and glucose metabolism in hypercholesterolemia patients with impaired glucose tolerance
2. To clarify beneficial patients of ezetimibe treatment
Safety,Efficacy
Exploratory
Pragmatic
Phase IV
Comparison of LDL-C level between groups
Changes and comparison of
each serum lipid level, Apolipo protein level, glucose metabolism level, laboratory test level, atherosclerosis index level, BMI, waist circumference, adverse event
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
YES
YES
Institution is considered as a block.
YES
Central registration
2
Treatment
Medicine |
Statin treatment
Rosuvastatin 5mg
Combination treatment
Rosuvastatin 2.5mg + ezetimibe 10mg
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1) LDL-C level exceeds target LDL-C level(Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2007) after at least 4 weeks of rosuvastatin treatment
2) 5.5%<=HbA1c(NGSP)<6.5% or 110mg/dL<=fasting blood glucose<126mg/dL
1) HbA1c>=6.5%(NGSP)
2) Hypersensitivity to test agents
3) Treating with antihyperlipidemic agents other than rosuvastatin
4) Severe hepatic dysfunction: any one of following
(i)AST>=100IU/L
(ii)ALT>=100IU/L
(iii)Cirrhosis
5) Severe renal dysfunction: serum creatinine>=2.0mg/dL
6) History of acute coronary syndrome(myocardial infarction, angina) and stroke within 3 months
7) Secondary hyperlipidemia, drug induced hyperlipidemia
8) Pregnant, breast-feeding, becoming pregnant
9) Familial hypercholesterolemia
10) Inadequate to this study
150
1st name | |
Middle name | |
Last name | Mitsuyuki SHIMIZU |
Jikei University School of Medicine,Kashiwa Hospital
Division of Cardiology Department of Internal Medicine
163-1, Kashiwashita, Kashiwa city, Chiba
04-7164-1111
1st name | |
Middle name | |
Last name | Mitsuyuki SHIMIZU |
Jikei University School of Medicine,Kashiwa Hospital
Division of Cardiology Department of Internal Medicine
163-1, Kashiwashita, Kashiwa city, Chiba
04-7164-1111
Jikei University School of Medicine,Kashiwa Hospital
None
Self funding
Kashiwa Heart Clinic
Fujiki Clinic
Takeda Clinic
Nedo Clinic
NO
東京慈恵会医科大学付属柏病院(千葉県)
東京慈恵会医科大学附属病院(東京都)
医療法人社団 慈雅会 柏ハートクリニック(千葉県)
医療法人社団 藤木医院(千葉県)
竹田内科医院(千葉県)
根戸クリニック(千葉県)
2012 | Year | 05 | Month | 30 | Day |
Unpublished
Terminated
2011 | Year | 07 | Month | 22 | Day |
2011 | Year | 10 | Month | 01 | Day |
2012 | Year | 12 | Month | 01 | Day |
2012 | Year | 05 | Month | 29 | Day |
2016 | Year | 08 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009480